DongKoo Bio & Pharma Co., Ltd.
Financials
Valuation Metrics
DongKoo Bio & Pharma Co., Ltd.'s Market Cap is ₩1124B. At end of 2025 it was ₩1557B. Ranked #1148 of 2,436 in KR market (top 47%), #595 of 1,649 on KOSDAQ (top 36%), #135 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 58%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 112.44B KRW | KR#1,148/2,436 Sec#135/234 |
| Revenue | 242.08B KRW | KR#924/2,436 Sec#50/234 |
| Net Income | 50.32B KRW | KR#366/2,436 Sec#26/234 |
| Total Assets | 339.54B KRW | KR#940/2,436 Sec#58/234 |
| Employees | 418 | KR#581/2,436 Sec#48/234 |
| Value | ||
| P/E | 2.23x | KR#64/2,436 Sec#1/234 |
| P/S | 0.46x | KR#877/2,436 Sec#33/234 |
| EV/EBITDA | 24.86x | KR#1,123/2,436 Sec#70/234 |
| FCF Yield | -19.52% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROA | 14.82% | KR#77/2,436 Sec#10/234 |
| Op. Margin | 3.60% | KR#1,125/2,436 Sec#86/234 |
| Revenue Growth | -1.04% | KR#1,508/2,436 Sec#144/234 |
| Financial Health | ||
| Total Debt | 127.14B KRW | KR#633/2,436 Sec#34/234 |
| FCF | -21.94B KRW | KR#1,917/2,436 Sec#183/234 |
| Cash | 22.74B KRW | KR#1,163/2,436 Sec#83/234 |
| Current Ratio | 0.77x | KR#2,075/2,436 Sec#199/234 |
| Net Debt/EBITDA | 11.97x | KR#1,321/2,436 Sec#95/234 |
| Dividend | ||
| Div. Yield | 3.12% | KR#626/2,436 Sec#29/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -21.16% | KR#1,280/2,436 Sec#105/234 |
| 1M Return | 4.50% | KR#493/2,436 Sec#35/234 |
| From 52W High | -38.18% | KR#661/2,436 Sec#49/234 |
| 1Y MDD | -42.45% | KR#610/2,436 Sec#47/234 |
| Trading | ||
| Volume | 78,082 shares | KR#1,028/2,436 Sec#98/234 |
| Foreign Own. | 3.75% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 1,770 KRW | KR#431/2,436 Sec#28/234 |
| BPS | 5,476 KRW | KR#1,373/2,436 Sec#100/234 |
Company Info
Established in 1983 for the manufacturing and sale of finished pharmaceuticals, the company was listed on KOSDAQ in 2018 and holds 5 consolidated subsidiaries, including Loftyrock Investment. It operates a four-business unit system: Pharmaceuticals, focusing on manufacturing and selling professional pharmaceuticals and quasi-drugs; Finance; Medical Services; and Pharmaceutical Wholesale and Consulting. The company maintains its #1 position in dermatology prescriptions, possesses differentiated manufacturing technology, and is actively pursuing entry into the cosmeceutical market and overseas expansion.